クロストリジウムディフィシル検査の世界市場：市場規模（セグメント別）、シェア、規制、償還、予測（～2036年）

当レポートでは、世界のクロストリジウムディフィシル検査市場について調査分析し、各地域の市場規模、主要動向、革新的な製品と技術、競合情勢などの情報を提供しています。

市場モデルの主な内容は以下の通りです。

上市済みのクロストリジウムディフィシル検査と進化する競合情勢

• 主な業界動向の考察
• クロストリジウムディフィシル検査市場の各セグメントの年間収益と市場見通し（2015年～2036年）
• ユニット数、平均販売価格、市場金額に関する市場レベルのデータ

世界、地域、国レベルの各市場の考察

• 世界の動向を地域ごとに分類した定性的な各市場の情報と各国の市場の考察
• クロストリジウムディフィシル検査市場のSWOT分析
• クロストリジウムディフィシル検査市場の競合力学の考察と動向

医療制度の概要を含む真の全体像を把握することで、市場の理解を促進します。また、市場参入セグメントでは、償還政策や規制情勢についての情報を提供し、市場力学をより深く掘り下げることができます。

• 各国の医療制度の概要
• 各国の償還政策
• 各国の医療技術に関する規制情勢

対象企業

• bioMerieux SA
• Meridian Bioscience Inc
• TECHLAB Inc
• Thermo Fisher Scientific Inc
• LG Life Science LTD
• Leica Microsystems Inc + Luminex Corp
• DiaSorin Molecular LLC + Luminex Corp
• Microbiologics Inc
• American Type Culture Collection
• その他

Clostridium Difficile Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036 is built to visualise quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.

Clostridium difficile Tests are carried out to diagnose the bacterium, commonly known as C. diff, that is a major cause of serious diarrheal infections, and may also cause colon cancer. Clostridium difficile Infection (CDI) is contagious and causes symptoms such as prolonged and frequent diarrhoea or watery stools, as well as pain or tenderness in the stomach, loss of appetite, fever and nausea.

People who are susceptible to CDI include the geriatric population, people with prolonged exposure to antibiotics, individuals recovering from recent hospitalization, people with weakened immunity, or those who have been infected with C. difficile in the past.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with installed base. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insights offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Clostridium difficile Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Clostridium difficile Tests market revenue by segment and market outlooks from 2015-2036.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Clostridium Difficile Tests market.
• Competitive dynamics insights and trends provided for Clostridium Difficile Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: bioMerieux SA, Meridian Bioscience Inc, TECHLAB Inc, Thermo Fisher Scientific Inc, LG Life Science LTD, Leica Microsystems Inc + Luminex Corp, DiaSorin Molecular LLC + Luminex Corp, Microbiologics Inc, American Type Culture Collection, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Clostridium Difficile Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving Clostridium Difficile Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Clostridium Difficile Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Clostridium Difficile Tests market from 2015-2036.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Not Applicable